Announced
Financials
Sources
Tags
Germany
Private Equity
Pending
pharma
Acquisition
Cross Border
biotechnology
Private
Majority
Biotechnology
Friendly
Single Bidder
Synopsis
KKR and Flerie, an investment firm, agreed to invest in Coriolis Pharma, a biotechnology company. Financial terms were not disclosed. “This investment presents a pivotal growth opportunity for Coriolis to realize our strategy and vision. The ability to leverage Frontier’s collective skills and expertise will be invaluable as we revolutionize the development process of biopharmaceutical drugs. Together with a strong suite of industry advisors and KKR's global network and market knowledge, we will be able to position Coriolis for the future and move one step closer to our goal of making future therapies available to humankind efficiently and on time,” Michael Wiggenhorn, Coriolis Pharma Co-Founder.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.